Merck out, Merck in
This article was originally published in Scrip
Elmar Schnee, head of Merck KGaA's pharmaceuticals unit, is stepping down to be replaced by the head of emerging markets at US rival Merck & Co, Stefan Oschmann. Mr Schnee was said to be leaving "for personal reasons". In line with his predecessor, Mr Oschmann will be responsible for both the Merck Serono and Consumer Health Care divisions of the German firm. Merck KGaA has suffered a series of clinical setbacks of late. Last month, the US FDA extended its review period for the company's multiple sclerosis pill cladribine, which was rejected by the EU's CHMP in September.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.